Keyword search
Filter results by
Search HelpKeyword(s)
Subject
Survey or statistical program
Results
All (4)
All (4) ((4 results))
- 1. A discussion of the emerging nanotechnology ArchivedArticles and reports: 88-003-X20030026561Geography: CanadaDescription:
Nanotechnology is an emerging technology. Has it reached the point that warrants the development of a comprehensive statistical measurement program? If so, what indicators should be used? Major spending initiatives in nanotechnology investing are currently underway. There is precedence for using developed methods and techniques to address the questions 'who,' 'what,' 'where' and 'why.' Statistics Canada's experience may be invaluable in the development of a nanotechnology statistical program.
Release date: 2003-06-27 - Articles and reports: 88-003-X20030026570Geography: CanadaDescription:
In 2001, Canadian biotech firms raised $980 million in financing capital, a sharp drop from the $2.1 billion raised in 1999. Overall, 114 firms out of 188 (61%) that attempted to raise capital either failed or did not reach their targets. Why are biotech firms encountering difficulties in raising financing capital?
Release date: 2003-06-27 - 3. Use of biotechnology in Canadian industry ArchivedArticles and reports: 88-003-X20020016152Geography: CanadaDescription:
The Biotechnology Use & Development Survey-1999 provides insights into the transition from R&D to the commercial use of a technology in products and processes. Improvement in product quality is reported as the number one benefit derived from using biotechnologies. This article explores some of the characteristics of the firms that use biotechnologies addressing the questions: "Why use biotechnology?" and "Why not use biotechnology?"
Release date: 2002-02-15 - Articles and reports: 88-003-X20000035772Geography: CanadaDescription:
Technological change and innovations depend greatly on R&D activities and investments. R&D is concentrated around the "core firms" that are responsible for 87% of expenditures. Biotechnology R&D performers accounted for $904 million of R&D expenditure. Biotechnology R&D is concentrated in large firms with 75% of R&D occuring in firms with 100 or more employees. Almost 77% of funding sources for R&D in biotechnology came from the private sector and 21% from foreign sources.
Release date: 2000-10-06
Data (0)
Data (0) (0 results)
No content available at this time.
Analysis (4)
Analysis (4) ((4 results))
- 1. A discussion of the emerging nanotechnology ArchivedArticles and reports: 88-003-X20030026561Geography: CanadaDescription:
Nanotechnology is an emerging technology. Has it reached the point that warrants the development of a comprehensive statistical measurement program? If so, what indicators should be used? Major spending initiatives in nanotechnology investing are currently underway. There is precedence for using developed methods and techniques to address the questions 'who,' 'what,' 'where' and 'why.' Statistics Canada's experience may be invaluable in the development of a nanotechnology statistical program.
Release date: 2003-06-27 - Articles and reports: 88-003-X20030026570Geography: CanadaDescription:
In 2001, Canadian biotech firms raised $980 million in financing capital, a sharp drop from the $2.1 billion raised in 1999. Overall, 114 firms out of 188 (61%) that attempted to raise capital either failed or did not reach their targets. Why are biotech firms encountering difficulties in raising financing capital?
Release date: 2003-06-27 - 3. Use of biotechnology in Canadian industry ArchivedArticles and reports: 88-003-X20020016152Geography: CanadaDescription:
The Biotechnology Use & Development Survey-1999 provides insights into the transition from R&D to the commercial use of a technology in products and processes. Improvement in product quality is reported as the number one benefit derived from using biotechnologies. This article explores some of the characteristics of the firms that use biotechnologies addressing the questions: "Why use biotechnology?" and "Why not use biotechnology?"
Release date: 2002-02-15 - Articles and reports: 88-003-X20000035772Geography: CanadaDescription:
Technological change and innovations depend greatly on R&D activities and investments. R&D is concentrated around the "core firms" that are responsible for 87% of expenditures. Biotechnology R&D performers accounted for $904 million of R&D expenditure. Biotechnology R&D is concentrated in large firms with 75% of R&D occuring in firms with 100 or more employees. Almost 77% of funding sources for R&D in biotechnology came from the private sector and 21% from foreign sources.
Release date: 2000-10-06
Reference (0)
Reference (0) (0 results)
No content available at this time.
- Date modified: